Appealing a July ruling against the regulation, the U.S. Department of Health and Human Services (HHS) is revisiting its proposed mandate requiring drug prices in television advertisements, a cornerstone of the Trump administration’s drug pricing plan.
The blocked regulation would require pharmaceutical companies to include sticker prices in TV ads for drugs costing more than $35 for a month’s supply. Federal judge Amit Mehta ruled against the proposal on July 8, when he uncovered that Congress had not authorized HHS to require the price disclosures.
The latest appeal renews the fight between drug manufacturers and the Trump administration. Regulators hope the mandate will provide greater transparency and encourage patients to discuss affordability with their doctors, pressuring drug makers to lower prices as a result. However, drug makers argue that most consumers don’t pay the sticker price for their medications, making this information irrelevant to include in their advertising.